Iacobelli, S
de Wreede, L C
Schönland, S
Björkstrand, B
Hegenbart, U
Gruber, A
Greinix, H
Volin, L
Narni, F
Carella, A M
Beksac, M
Bosi, A
Milone, G
Corradini, P
Friberg, K
van Biezen, A
Goldschmidt, H
de Witte, T
Morris, C
Niederwieser, D
Garderet, L
Kröger, N
Gahrton, G
,
Article History
Received: 6 October 2014
Revised: 27 November 2014
Accepted: 2 December 2014
First Online: 26 January 2015
Competing interests
: UH: Janssen and Binding Site—received personal fees outside the submitted work. SS: Janssen, Celgene and Binding Site– received personal fees outside the submitted work. PC: Celgene—Honoraria. HG: Janssen—advisory board, speakers bureau, research support; Celgene—advisory board, speakers bureau, research support; Novartis—advisory board, speakers bureau, research support; Chugai—speakers bureau, research support; Onyx—advisory board, speakers bureau; Millenium—advisory board, speakers bureau. GG: Fujimoto Pharmaceutical Cooperation Japan—consultant or advisory relationship; Celgene—Honoraria, research funding. The other authors have no conflicts of interest.